Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
Ana C. Puhl, André S. Godoy, G.D. Noske, et al.
ACS Omega (2023) Vol. 8, Iss. 25, pp. 22603-22612
Open Access | Times Cited: 12

Showing 12 citing articles:

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 5
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 5
Applications of Machine Learning Approaches for the Discovery of SARS-CoV-2 PLpro Inhibitors
Sourav Pal, Kellie D. Nance, Dirgha Raj Joshi, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
In Silico and In Vitro Studies of the Approved Antibiotic Ceftaroline Fosamil and Its Metabolites as Inhibitors of SARS-CoV-2 Replication
Cássia P. Delgado, Pablo A. Nogara, Milene Dias Miranda, et al.
Viruses (2025) Vol. 17, Iss. 4, pp. 491-491
Open Access
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 10
In Silico and In Vitro Studies of Terpenes from the Fabaceae Family Using the Phenotypic Screening Model against the SARS-CoV-2 Virus
Natália Ferreira de Sousa, Gabrielly Diniz Duarte, Carolina Borsoi Moraes, et al.
Pharmaceutics (2024) Vol. 16, Iss. 7, pp. 912-912
Open Access | Times Cited: 1
Learning from COVID-19: How drug hunters can prepare for the next pandemic
Ana C. Puhl, Thomas R. Lane, Sean Ekins
Drug Discovery Today (2023) Vol. 28, Iss. 10, pp. 103723-103723
Open Access | Times Cited: 3
A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition
Katrina Forrestall, Eric S. Pringle, Dane Sands, et al.
Antiviral Research (2023) Vol. 220, pp. 105758-105758
Closed Access | Times Cited: 3
Drug-target prediction through self supervised learning with dual task ensemble approach
Surabhi Mishra, Ashish Chinthala, Mahua Bhattacharya
Computational Biology and Chemistry (2024) Vol. 113, pp. 108244-108244
Closed Access
Phthalimide derivatives as a new class of papain‐like protease inhibitors in SARS‐CoV‐2
Thomas Fischer, David Frasson, Martin Sievers, et al.
Archiv der Pharmazie (2024)
Closed Access
Multi‐Targeted Antivirals
Bing Ye, Letian Song, Meehyein Kim, et al.
(2024), pp. 405-421
Closed Access
Dual inhibition of coronavirus Mproand PLproenzymes by phenothiazines and their antiviral activity
Katrina Forrestall, Eric S. Pringle, Dane Sands, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top